• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Biotricity Inc.

    8/8/24 6:09:48 PM ET
    $BTCY
    Medical/Dental Instruments
    Health Care
    Get the next $BTCY alert in real time by email
    SC 13G 1 g084387_sch13g.htm SC 13G

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934
    (Amendment No. )*

     

    Biotricity Inc.

     

    (Name of Issuer)

     

    Common Stock, par value $0.001 per share

     

    (Title of Class of Securities)

     

    09074H203

     

    (CUSIP Number)

     

    July 8, 2024

     

    (Date of Event which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ☐ Rule 13d-1(b)
    ☒ Rule 13d-1(c)
    ☐ Rule 13d-1(d)

     

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

    CUSIP No. 09074H203   13G   Page 2 of 10 Pages

     

    1. NAMES OF REPORTING PERSONS

    Ionic Ventures, LLC
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (see instructions)
    (a)    ☒
    (b)    ☐
    3. SEC USE ONLY
     
    4. CITIZENSHIP OR PLACE OF ORGANIZATION
     
    California, United States

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5. SOLE VOTING POWER
     
    0
    6.

    SHARED VOTING POWER

     

    2,421,259 (1) 

    7. SOLE DISPOSITIVE POWER
     
    0
    8.

    SHARED DISPOSITIVE POWER

     

    2,421,259 (1) 

    9.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    2,421,259 (1) 

    10. CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
    (see instructions)    ☐
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    9.9% (1)
    12. TYPE OF REPORTING PERSON (see instructions)

    OO

     

      (1) As more fully described in Item 4 of this Statement on Schedule 13G (this “Schedule 13G”), such shares and percentage are based on 22,271,865 outstanding shares of the issuer’s common stock, par value $0.001 per share (the “Common Stock”), as disclosed in the issuer’s definitive proxy statement on Schedule 14A, filed by the issuer with the U.S. Securities and Exchange Commission (the “SEC”) on August 5, 2024 (the “Proxy Statement”). Consists of (i) 456,291 shares of Common Stock held by the reporting person and (ii) an aggregate of up to 1,964,968 shares of Common Stock (the “Conversion Shares”) issuable upon conversion of the shares of Series B Convertible Preferred Stock, par value $0.001, of the issuer (the “Preferred Stock”) held by the reporting person, which shares of Preferred Stock are convertible at any time into shares of Common Stock, subject to a 9.99% beneficial ownership blocker (the “Blocker”) contained in the issuer’s Certificate of Designations of the Preferred Stock (the “Certificate of Designations”).

     

     

     

    CUSIP No. 09074H203   13G   Page 3 of 10 Pages

     

    1.

    NAMES OF REPORTING PERSONS

     

    Ionic Management, LLC

    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (see instructions)
    (a)    ☒
    (b)    ☐
    3. SEC USE ONLY
     
    4. CITIZENSHIP OR PLACE OF ORGANIZATION
     
    Delaware, United States
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5. SOLE VOTING POWER
     
    0
    6.

    SHARED VOTING POWER

     

    2,421,259 (1)  

    7. SOLE DISPOSITIVE POWER
     
    0
    8.

    SHARED DISPOSITIVE POWER

     

    2,421,259 (1) 

    9.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    2,421,259 (1) 

    10. CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
    (see instructions)    ☐
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    9.9% (1)
    12. TYPE OF REPORTING PERSON (see instructions)

    OO

     

      (1) As more fully described in Item 4 of this Schedule 13G, such shares and percentage are based on 22,271,865 outstanding shares of Common Stock, as disclosed in the Proxy Statement. Consists of (i) 456,291 shares of Common Stock indirectly held by the reporting person and (ii) an aggregate of up to 1,964,968 Conversion Shares issuable upon conversion of the Preferred Stock indirectly held by the reporting person, which shares of Preferred Stock are convertible at any time into shares of Common Stock, subject to the 9.99% Blocker contained in the Certificate of Designations.

     

     

     

    CUSIP No. 09074H203   13G   Page 4 of 10 Pages

     

    1. NAMES OF REPORTING PERSONS

    Brendan O’Neil
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (see instructions)
    (a)    ☒
    (b)    ☐
    3. SEC USE ONLY
     
    4. CITIZENSHIP OR PLACE OF ORGANIZATION
     
    United States
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5. SOLE VOTING POWER
     
    0
    6.

    SHARED VOTING POWER

     

    2,421,259 (1) 

    7. SOLE DISPOSITIVE POWER
     
    0
    8.

    SHARED DISPOSITIVE POWER

     

    2,421,259 (1) 

    9.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    2,421,259 (1) 

    10. CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
    (see instructions)    ☐
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    9.9% (1)
    12. TYPE OF REPORTING PERSON (see instructions)

    IN

     

      (1) As more fully described in Item 4 of this Schedule 13G, such shares and percentage are based on 22,271,865 outstanding shares of Common Stock, as disclosed in the Proxy Statement. Consists of (i) 456,291 shares of Common Stock indirectly held by the reporting person and (ii) an aggregate of up to 1,964,968 Conversion Shares issuable upon conversion of the Preferred Stock indirectly held by the reporting person, which shares of Preferred Stock are convertible at any time into shares of Common Stock, subject to the 9.99% Blocker contained in the Certificate of Designations.

     

     

     

    CUSIP No. 09074H203   13G   Page 5 of 10 Pages

     

    1. NAMES OF REPORTING PERSONS

    Keith Coulston
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (see instructions)
    (a)    ☒
    (b)    ☐
    3. SEC USE ONLY
     
    4. CITIZENSHIP OR PLACE OF ORGANIZATION
     
    United States
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5. SOLE VOTING POWER
     
    0
    6.

    SHARED VOTING POWER

     

    2,421,259 (1) 

    7. SOLE DISPOSITIVE POWER
     
    0
    8.

    SHARED DISPOSITIVE POWER

     

    2,421,259 (1) 

    9.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    2,421,259 (1) 

    10. CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
    (see instructions)    ☐
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    9.9% (1)
    12. TYPE OF REPORTING PERSON (see instructions)

    IN

     

      (1) As more fully described in Item 4 of this Schedule 13G, such shares and percentage are based on 22,271,865 outstanding shares of Common Stock, as disclosed in the Proxy Statement. Consists of (i) 456,291 shares of Common Stock indirectly held by the reporting person and (ii) an aggregate of up to 1,964,968 Conversion Shares issuable upon conversion of the Preferred Stock indirectly held by the reporting person, which shares of Preferred Stock are convertible at any time into shares of Common Stock, subject to the 9.99% Blocker contained in the Certificate of Designations.

     

     

     

    CUSIP No. 09074H203   13G   Page 6 of 10 Pages

       

    Item 1(a). Name of Issuer:

     

    Biotricity Inc. (the “Issuer”).

     

    Item 1(b). Address of Issuer’s Principal Executive Offices:

     

    The Issuer’s principal executive office is located at 203 Redwood Shores Parkway, Suite 600, Redwood City, California 94065.

     

    Item 2(a). Names of Persons Filing:

     

      (i) Ionic Ventures LLC, a California limited liability company (“Ionic”);
       
      (ii) Ionic Management, LLC, a Delaware limited liability company (“Ionic Management”);
       
      (iii) Brendan O’Neil (“Mr. O’Neil”); and
       
      (iv) Keith Coulston (“Mr. Coulston”).

     

    The foregoing persons are hereinafter collectively referred to as the “Reporting Persons”. Any disclosures herein with respect to persons other than the Reporting Persons are made on information and belief after making inquiry to the appropriate party.

     

    The Reporting Persons have entered into a Joint Filing Agreement, a copy of which is filed as Exhibit 1 to this Schedule 13G, pursuant to which such Reporting Persons have agreed to file this Schedule 13G and all subsequent amendments to the Schedule 13G jointly in accordance with the provisions of Rule 13d-1(k) of the Act.

     

    The filing of this Schedule 13G should not be construed in and of itself as an admission by any Reporting Person as to beneficial ownership of the shares of the Common Stock reported herein.  

     

    Item 2(b). Address of Principal Business Office or, if none, Residence:

     

    The principal business address of each of the Reporting Persons is 3053 Fillmore St, Suite 256, San Francisco, CA 94123.

     

    Item 2(c). Citizenship:

     

    Ionic is a limited liability company organized under the laws of California. Ionic Management is a limited liability company organized under the laws of the State of Delaware. Each of Mr. Coulston and Mr. O’Neil is a citizen of the United States.

     

    Item 2(d). Title of Class of Securities:

     

    The title of the class of securities to which this Schedule 13G relates is the Issuer’s common stock, par value $0.001 per share.

     

     

     

       

    CUSIP No. 09074H203   13G   Page 7 of 10 Pages

     

    Item 2(e). CUSIP Number: 09074H203

     

    Item 3. If This Statement is Filed Pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), Check Whether the Person Filing is a:

     

    Not applicable.

     

    Item 4. Ownership.

     

    The information required by this item with respect to each Reporting Person is set forth in Rows 5 through 9 and 11 of the cover pages to this Schedule 13G and is incorporated herein by reference for each such Reporting Person. The ownership percentages reported are based on (i) 22,271,865 shares of Common Stock outstanding, as reported in the Issuer’s definitive proxy statement on Schedule 14A, filed by the Issuer with the SEC on August 5, 2024, and (ii) up to 1,964,968 Conversion Shares issuable upon conversion of shares of Preferred Stock held by Ionic, which further conversions thereof are subject to the 9.99% Blocker contained in the Certificate of Designations.

     

    Ionic holds (i) 456,291 shares of Common Stock and (ii) 435 shares of Preferred Stock. Pursuant to the terms of the Certificate of Designations, within sixty days of the date of the filing of this Schedule 13G, up to an aggregate of $2,250,000 of such shares of Preferred Stock are convertible into up to 6,081,082 shares of Common Stock, based on an Alternate Conversion Price (as defined in the Certificate of Designations) of $0.37 per share as of August 7, 2024, of which 4,116,114 shares of Common Stock are not deemed beneficially owned by Ionic as a result of the triggering of the Blocker, which prohibits Ionic from converting its shares of Preferred Stock into shares of Common Stock if, as a result of such conversion, the holder, together with its affiliates and any persons acting as a group together with such holder or any of such affiliates, would beneficially own more than 9.99% of the total number of shares of Common Stock then issued and outstanding immediately after giving effect to such conversion. In addition, an aggregate of $2,100,000 shares of Preferred Stock convertible into up to 5,675,676 shares of Common Stock (based on an Alternate Conversion Price of $0.37 per share) are not deemed beneficially owned by Ionic as a result of the limitation imposed on the number of Conversion Notices (as defined in the Certificate of Designations) that may be delivered by Ionic within sixty days of the date of the filing of this Schedule 13G based on the five-day Alternate Conversion Measuring Period (as defined in the Certificate of Designations).

     

    Ionic is the beneficial owner of 2,421,259 shares of Common Stock (the “Shares”). Ionic has the power to dispose of and the power to vote the Shares beneficially owned by it, which power may be exercised by its manager, Ionic Management. Each of the managers of Ionic Management, Mr. O’Neil and Mr. Coulston, has shared power to vote and/or dispose of the Shares beneficially owned by Ionic and Ionic Management. Neither Mr. O’Neil nor Mr. Coulston directly owns the Shares. By reason of the provisions of Rule 13d-3 of the Act, each of Mr. O’Neil and Mr. Coulston may be deemed to beneficially own the Shares which are beneficially owned by each of Ionic and Ionic Management, and Ionic Management may be deemed to beneficially own the Shares which are beneficially owned by Ionic.

     

    Item 5. Ownership of Five Percent or Less of a Class.

     

    Not applicable.

     

    Item 6. Ownership of More than Five Percent on Behalf of Another Person.

     

    Not applicable.

     

     

     

    CUSIP No. 09074H203   13G   Page 8 of 10 Pages

     

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.

     

    Not applicable.

     

    Item 8. Identification and Classification of Members of the Group.

     

    Not applicable.

     

    Item 9. Notice of Dissolution of Group.

     

    Not applicable.

     

    Item 10. Certification.

     

    By signing below each of the Reporting Persons certify that, to the best of each of their knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

     

     

     

    CUSIP No. 09074H203   13G   Page 9 of 10 Pages

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this Statement is true, complete and correct.

     

    Date: August 8, 2024 IONIC VENTURES, LLC
       
      By: Ionic Management, LLC,
        its Manager
       
      By: /s/ Keith Coulston
        Name: Keith Coulston
        Title: Manager
       
      IONIC MANAGEMENT, LLC
       
      By: /s/ Keith Coulston
        Name: Keith Coulston
        Title: Manager
         
      /s/ Brendan O’Neil
      Brendan O’Neil
         
      /s/ Keith Coulston
      Keith Coulston

     

     

    CUSIP No. 09074H203   13G   Page 10 of 10 Pages

     

    EXHIBIT 1

     

    JOINT FILING AGREEMENT 

    PURSUANT TO RULE 13d-1(k)

     

    The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing agreements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained herein and therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate. The undersigned hereby further agree that this Joint Filing Agreement may be executed in any number of counterparts, each of which when so executed shall be deemed to be an original, but all of which counterparts shall together constitute one and the same instrument.

     

    Date: August 8, 2024 IONIC VENTURES, LLC
       
      By: Ionic Management, LLC,
             its Manager
       
      By: /s/ Keith Coulston
        Name: Keith Coulston
        Title: Manager
       
      IONIC MANAGEMENT, LLC
       
      By: /s/ Keith Coulston
        Name: Keith Coulston
        Title: Manager
         
      /s/ Brendan O’Neil
      Brendan O’Neil
         
      /s/ Keith Coulston
      Keith Coulston

     

     

    Get the next $BTCY alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $BTCY

    DatePrice TargetRatingAnalyst
    11/20/2023Buy → Neutral
    H.C. Wainwright
    3/7/2022$5.00Buy
    Lake Street
    11/23/2021$6.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $BTCY
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Biotricity Recognized by Financial Times as One of 2025's Fastest-Growing Companies in the Americas, Growing 256.4% Over the Period Analyzed

      REDWOOD CITY, Calif., April 08, 2025 (GLOBE NEWSWIRE) -- Biotricity Inc. (OTCQB:BTCY) a leading Technology-as-a-Service (Taas) company specializing in cutting-edge diagnostic and chronic disease management solutions for healthcare providers and consumers, is proud to announce its inclusion on the Financial Times' list of The Americas' Fastest-Growing Companies 2025. This recognition highlights Biotricity's innovation in digital health and exceptional growth of 256.4% during a period marked by unprecedented global challenges. Now in its sixth year, the Financial Times, in partnership with the research firm Statista, evaluated independent companies across the Americas based on disclosed rev

      4/8/25 8:15:00 AM ET
      $BTCY
      Medical/Dental Instruments
      Health Care
    • Biotricity Expands IP Portfolio & Strategy with 14 New Patents, Reinforcing Innovation & Leadership in Remote Monitoring, Diagnostics, & Chronic Disease Management

      Biotricity's latest patents focus on a multi-biometric device platform that functions as both a patch and watch, advancing biometric monitoring solutions for remote patient care. REDWOOD CITY, Calif., March 12, 2025 (GLOBE NEWSWIRE) -- Biotricity Inc. (OTCQB:BTCY), ("Biotricity" or the "Company"), a leading Technology-as-a-Service (Taas) company specializing in cutting-edge diagnostic and chronic disease management solutions for healthcare providers and consumers, is proud to announce the expansion of its intellectual property (IP) portfolio with 14 new patents. This brings the company's total to 15 issued patents, with an additional 14 patents pending. The expansion of the company's IP p

      3/12/25 8:15:00 AM ET
      $BTCY
      Medical/Dental Instruments
      Health Care
    • Biotricity Delivers Record Margins, Record Revenues, and Record Cashflows with 21.7% Year-Over-Year Sales Growth for its Third Quarter of Fiscal 2025

      Company reports Q3-FY25 revenue grew by 21.7% YOY to $3.6 millionManagement continues to drive revenues and efficienciesCompany achieved positive cash flow on current operating basis, before paying interest, dividends and amortization for the second consecutive quarter, up 114.5% from the prior quarter; management expects to continue to see cash flows improveRecurring technology fees, existing and new customer sales see continued growthReduced SG&A to $2.38 million from $3.0 million, down 20.5% compared to the same period last yearGross margins continued to meet management expectations for improvement at 76.4%, a significant improvement from 72.9% for the same period last yearRecurring Techn

      2/20/25 8:15:00 AM ET
      $BTCY
      Medical/Dental Instruments
      Health Care

    $BTCY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Biotricity Inc.

      SC 13G/A - BIOTRICITY INC. (0001630113) (Subject)

      11/14/24 6:06:28 PM ET
      $BTCY
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G filed by Biotricity Inc.

      SC 13G - BIOTRICITY INC. (0001630113) (Subject)

      8/8/24 6:09:48 PM ET
      $BTCY
      Medical/Dental Instruments
      Health Care

    $BTCY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Biotricity downgraded by H.C. Wainwright

      H.C. Wainwright downgraded Biotricity from Buy to Neutral

      11/20/23 7:21:43 AM ET
      $BTCY
      Medical/Dental Instruments
      Health Care
    • Lake Street initiated coverage on Biotricity with a new price target

      Lake Street initiated coverage of Biotricity with a rating of Buy and set a new price target of $5.00

      3/7/22 9:01:18 AM ET
      $BTCY
      Medical/Dental Instruments
      Health Care
    • HC Wainwright & Co. initiated coverage on Biotricity with a new price target

      HC Wainwright & Co. initiated coverage of Biotricity with a rating of Buy and set a new price target of $6.00

      11/23/21 6:29:32 AM ET
      $BTCY
      Medical/Dental Instruments
      Health Care

    $BTCY
    SEC Filings

    See more
    • Amendment: SEC Form 10-Q/A filed by Biotricity Inc.

      10-Q/A - BIOTRICITY INC. (0001630113) (Filer)

      2/20/25 12:08:33 PM ET
      $BTCY
      Medical/Dental Instruments
      Health Care
    • SEC Form 10-Q filed by Biotricity Inc.

      10-Q - BIOTRICITY INC. (0001630113) (Filer)

      2/19/25 5:30:22 PM ET
      $BTCY
      Medical/Dental Instruments
      Health Care
    • SEC Form NT 10-Q filed by Biotricity Inc.

      NT 10-Q - BIOTRICITY INC. (0001630113) (Filer)

      2/14/25 5:11:11 PM ET
      $BTCY
      Medical/Dental Instruments
      Health Care

    $BTCY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Rosa David A

      4 - BIOTRICITY INC. (0001630113) (Issuer)

      3/15/23 4:22:52 PM ET
      $BTCY
      Medical/Dental Instruments
      Health Care
    • SEC Form 4 filed by Al-Siddiq Waqaas

      4 - BIOTRICITY INC. (0001630113) (Issuer)

      3/14/23 4:26:54 PM ET
      $BTCY
      Medical/Dental Instruments
      Health Care
    • SEC Form 4 filed by Ayanoglou John

      4 - BIOTRICITY INC. (0001630113) (Issuer)

      3/13/23 4:10:59 PM ET
      $BTCY
      Medical/Dental Instruments
      Health Care

    $BTCY
    Financials

    Live finance-specific insights

    See more
    • Biotricity Recognized by Financial Times as One of 2025's Fastest-Growing Companies in the Americas, Growing 256.4% Over the Period Analyzed

      REDWOOD CITY, Calif., April 08, 2025 (GLOBE NEWSWIRE) -- Biotricity Inc. (OTCQB:BTCY) a leading Technology-as-a-Service (Taas) company specializing in cutting-edge diagnostic and chronic disease management solutions for healthcare providers and consumers, is proud to announce its inclusion on the Financial Times' list of The Americas' Fastest-Growing Companies 2025. This recognition highlights Biotricity's innovation in digital health and exceptional growth of 256.4% during a period marked by unprecedented global challenges. Now in its sixth year, the Financial Times, in partnership with the research firm Statista, evaluated independent companies across the Americas based on disclosed rev

      4/8/25 8:15:00 AM ET
      $BTCY
      Medical/Dental Instruments
      Health Care
    • Biotricity Expands IP Portfolio & Strategy with 14 New Patents, Reinforcing Innovation & Leadership in Remote Monitoring, Diagnostics, & Chronic Disease Management

      Biotricity's latest patents focus on a multi-biometric device platform that functions as both a patch and watch, advancing biometric monitoring solutions for remote patient care. REDWOOD CITY, Calif., March 12, 2025 (GLOBE NEWSWIRE) -- Biotricity Inc. (OTCQB:BTCY), ("Biotricity" or the "Company"), a leading Technology-as-a-Service (Taas) company specializing in cutting-edge diagnostic and chronic disease management solutions for healthcare providers and consumers, is proud to announce the expansion of its intellectual property (IP) portfolio with 14 new patents. This brings the company's total to 15 issued patents, with an additional 14 patents pending. The expansion of the company's IP p

      3/12/25 8:15:00 AM ET
      $BTCY
      Medical/Dental Instruments
      Health Care
    • Biotricity Delivers Record Margins, Record Revenues, and Record Cashflows with 21.7% Year-Over-Year Sales Growth for its Third Quarter of Fiscal 2025

      Company reports Q3-FY25 revenue grew by 21.7% YOY to $3.6 millionManagement continues to drive revenues and efficienciesCompany achieved positive cash flow on current operating basis, before paying interest, dividends and amortization for the second consecutive quarter, up 114.5% from the prior quarter; management expects to continue to see cash flows improveRecurring technology fees, existing and new customer sales see continued growthReduced SG&A to $2.38 million from $3.0 million, down 20.5% compared to the same period last yearGross margins continued to meet management expectations for improvement at 76.4%, a significant improvement from 72.9% for the same period last yearRecurring Techn

      2/20/25 8:15:00 AM ET
      $BTCY
      Medical/Dental Instruments
      Health Care